CJC-1295 vs Tesamorelin
A side-by-side research comparison of CJC-1295 and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | FDA Approved |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 3,368 Da (without DAC) | 5,136 Da |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | 26-38 minutes |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-300 mcg | 2 mg |
| Frequency | 1-3x daily (no-DAC) | Once daily |
| Route | Subcutaneous injection | Subcutaneous injection |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.